{"log_id": 2251644447085459924, "direction": 0, "words_result_num": 39, "words_result": [{"probability": {"variance": 0.038335, "average": 0.841653, "min": 0.398571}, "location": {"width": 1248, "top": 146, "height": 64, "left": 274}, "words": "晚期实体患者中,口冰品5mg至70mg1~2小时达到浓度峰值。单药后,5mglg之间"}, {"probability": {"variance": 0.018744, "average": 0.87301, "min": 0.61281}, "location": {"width": 553, "top": 198, "height": 50, "left": 221}, "words": "的Cmx与剂量呈比例,削量为20mng及更高"}, {"probability": {"variance": 0.029688, "average": 0.857678, "min": 0.431498}, "location": {"width": 660, "top": 210, "height": 54, "left": 861}, "words": "增小于剂量升比例,但AC在5mg~70mg范围内"}, {"probability": {"variance": 0.034362, "average": 0.874025, "min": 0.386514}, "location": {"width": 628, "top": 253, "height": 50, "left": 230}, "words": "剂呈比例。每日一次给药后,于两内达到稳态"}, {"probability": {"variance": 0.022225, "average": 0.91959, "min": 0.419392}, "location": {"width": 1248, "top": 308, "height": 61, "left": 274}, "words": "结节性便化症相关的室芒膜下三胞星形细胞患者中的剂量比例:在结节性硬化相关的室管膜下"}, {"probability": {"variance": 0.032195, "average": 0.822972, "min": 0.39231}, "location": {"width": 486, "top": 361, "height": 50, "left": 221}, "words": "巨细胞星形细胞瘤患中:1.35mg/m至"}, {"probability": {"variance": 0.032128, "average": 0.794428, "min": 0.41436}, "location": {"width": 610, "top": 377, "height": 38, "left": 784}, "words": "gm量范围内,恢英可Cn大致与最成正比"}, {"probability": {"variance": 0.019412, "average": 0.855595, "min": 0.716269}, "location": {"width": 109, "top": 420, "height": 32, "left": 224}, "words": "食物"}, {"probability": {"variance": 0.030178, "average": 0.877677, "min": 0.364922}, "location": {"width": 1248, "top": 470, "height": 64, "left": 269}, "words": "在健康受试中,高脂降低本品10rg片剂全身露(ATC)的22,降低Cm54%低餐降低"}, {"probability": {"variance": 0.023097, "average": 0.896481, "min": 0.375023}, "location": {"width": 859, "top": 528, "height": 50, "left": 217}, "words": "AUC32%,降低C1342%。但食吸收段的药时曲线无明显影响"}, {"probability": {"variance": 4e-06, "average": 0.99785, "min": 0.9959}, "location": {"width": 57, "top": 582, "height": 32, "left": 217}, "words": "分布"}, {"probability": {"variance": 0.021512, "average": 0.861819, "min": 0.500019}, "location": {"width": 1248, "top": 637, "height": 59, "left": 267}, "words": "依维英的立液血浓度比(在5-0 piral范围内呈浓度赖生为17%-73。在给子本品10mg"}, {"probability": {"variance": 0.005687, "average": 0.962713, "min": 0.59195}, "location": {"width": 1300, "top": 690, "height": 59, "left": 212}, "words": "上次的癌症患者中,检测的依雏臭血浆浓度约为全血浓度的20%。健康试和中度肝功能受损患者的"}, {"probability": {"variance": 0.006477, "average": 0.962452, "min": 0.712301}, "location": {"width": 322, "top": 747, "height": 34, "left": 214}, "words": "血浆蛋结率均为约749"}, {"probability": {"variance": 3e-06, "average": 0.998154, "min": 0.996343}, "location": {"width": 57, "top": 802, "height": 29, "left": 212}, "words": "代谢"}, {"probability": {"variance": 0.037452, "average": 0.868639, "min": 0.353903}, "location": {"width": 1248, "top": 854, "height": 54, "left": 262}, "words": "依维莫是CYP3A和IPP底物。口股给药后,人体血循不中的主要成分是依维莫。在人血中已检测"}, {"probability": {"variance": 0.033236, "average": 0.8529, "min": 0.373733}, "location": {"width": 1293, "top": 907, "height": 57, "left": 210}, "words": "到依维莫的6个主要代产物:包三个单经装化代谢产物、2个水解开不产物和1个依维莫司磷指洗胆"}, {"probability": {"variance": 0.02512, "average": 0.915416, "min": 0.352972}, "location": {"width": 1289, "top": 964, "height": 52, "left": 210}, "words": "碱共化合物。在用毒理研究的动物科类中也发现了这些代谢产物,并显示代谢产活性比依维莫司活性"}, {"probability": {"variance": 0.004283, "average": 0.959305, "min": 0.829662}, "location": {"width": 139, "top": 1019, "height": 34, "left": 205}, "words": "约低10倍"}, {"probability": {"variance": 0.012689, "average": 0.921467, "min": 0.511584}, "location": {"width": 1238, "top": 1074, "height": 52, "left": 258}, "words": "在体外试5中,依维艾司宽性抑制CYP3A4的代谢活性,是CYP2D6底物右美沙芬的混合性抑制剂"}, {"probability": {"variance": 0.024796, "average": 0.890338, "min": 0.357576}, "location": {"width": 1195, "top": 1129, "height": 54, "left": 253}, "words": "g一次口服给药后,平均态Cx低于体外排制Ki12倍以上、因此,依维莫过太可能影响CYF"}, {"probability": {"variance": 0.000285, "average": 0.991137, "min": 0.944017}, "location": {"width": 283, "top": 1186, "height": 34, "left": 203}, "words": "CYP2底物的代谢"}, {"probability": {"variance": 0.009033, "average": 0.845852, "min": 0.750807}, "location": {"width": 59, "top": 1241, "height": 32, "left": 203}, "words": "排泄"}, {"probability": {"variance": 0.038485, "average": 0.867524, "min": 0.356918}, "location": {"width": 1243, "top": 1291, "height": 57, "left": 258}, "words": "尚没有在凝若中进行专门的排泄研究接受环菌素治疗植患考单次口服3mg放射标记的依维"}, {"probability": {"variance": 0.03299, "average": 0.864469, "min": 0.402506}, "location": {"width": 1293, "top": 1346, "height": 52, "left": 205}, "words": "莫后,E0的放封活性物经类便排出:5%经尿排泄。在尿和粪便小均没有检制出母体药物依维莫司平均"}, {"probability": {"variance": 0.03556, "average": 0.860764, "min": 0.42783}, "location": {"width": 274, "top": 1401, "height": 32, "left": 212}, "words": "肖院半期约为30小时"}, {"probability": {"variance": 0.012252, "average": 0.919656, "min": 0.734834}, "location": {"width": 194, "top": 1458, "height": 34, "left": 198}, "words": "稳态药代动力学"}, {"probability": {"variance": 0.037084, "average": 0.872389, "min": 0.377882}, "location": {"width": 1245, "top": 1508, "height": 57, "left": 251}, "words": "期实体瘤患老每日或周应用依维莫之后,在每日5全10mg结药范围内、每5至70mg药范围"}, {"probability": {"variance": 0.028861, "average": 0.886931, "min": 0.354024}, "location": {"width": 1298, "top": 1565, "height": 54, "left": 196}, "words": "内,稳态AC与剂量呈比例在每日给药案中于两周内达到德态,在每和每给药方中,5m至1mg"}, {"probability": {"variance": 0.030771, "average": 0.880597, "min": 0.353074}, "location": {"width": 1298, "top": 1620, "height": 52, "left": 196}, "words": "剂量范围之间,C与至比例。连20mg/周及更离水平时,Cx增加低于剂量比例。在给药后1-2"}, {"probability": {"variance": 0.030722, "average": 0.848673, "min": 0.3594}, "location": {"width": 1291, "top": 1673, "height": 54, "left": 203}, "words": "小时达到tx每约去到检态时:AUCa与药前谷浓腹之间有显著的关性,依维莫司的平均消除半"}, {"probability": {"variance": 0.027282, "average": 0.937237, "min": 0.445137}, "location": {"width": 242, "top": 1732, "height": 29, "left": 194}, "words": "长期大约是30小时。"}, {"probability": {"variance": 0.000436, "average": 0.987677, "min": 0.94049}, "location": {"width": 196, "top": 1783, "height": 36, "left": 192}, "words": "肾功能受损患者"}, {"probability": {"variance": 0.029559, "average": 0.893192, "min": 0.362074}, "location": {"width": 1248, "top": 1840, "height": 48, "left": 242}, "words": "际心的依维览司3mg后,约有5%的芯放射活性物经尿排泄:在170名晚症患者体药代"}, {"probability": {"variance": 0.020631, "average": 0.899025, "min": 0.417422}, "location": {"width": 1273, "top": 1892, "height": 50, "left": 189}, "words": "动力学分析中,凯酐滑除率25-178ml/分钟)没有著影依维莫表清除率(CLF)(参见【用法用量》"}, {"probability": {"variance": 0.013304, "average": 0.93671, "min": 0.663841}, "location": {"width": 192, "top": 1952, "height": 32, "left": 189}, "words": "肝功能受损患老"}, {"probability": {"variance": 0.010747, "average": 0.949963, "min": 0.4866}, "location": {"width": 1248, "top": 2004, "height": 50, "left": 240}, "words": "在一项山肝功能受以及肝功能正常受试考参加的研究中评估了单次口服本品的安全性,受性和药代"}, {"probability": {"variance": 0.017428, "average": 0.911927, "min": 0.524713}, "location": {"width": 800, "top": 2059, "height": 41, "left": 187}, "words": "动力学,发现与正常受试者=13)相比,轻度(C. ild-push A级"}, {"probability": {"variance": 0.027613, "average": 0.847473, "min": 0.641264}, "location": {"width": 274, "top": 2068, "height": 36, "left": 1110}, "words": "度( Childs- Pugh H级"}], "language": 3}